Measurement of abdominal symptoms by validated questionnaire: A 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframe

E. Rey, G. R. Locke, H. K. Jung, A. Malhotra, R. S. Choung, T. J. Beebe, C. D. Schleck, A. R. Zinsmeister, N. J. Talley

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background Rome III incorporates changes in the definition of functional gastrointestinal disorder that involve a 3-month recall time for symptoms, rather than 1-year. Aim To validate a new version of the Talley-Bowel Disease Questionnaire (Talley-BDQ) and assess the impact of recall time period on the prevalence of symptoms. Methods A sample of community residents were randomly mailed a survey using 1-year (n = 396) or 3-month recall period (n = 374). We evaluated the reliability and the concurrent validity of the two versions of the questionnaire. The proportions of subjects reporting symptoms in the two versions were compared. Results The median (IQR) kappa on symptom-related questions was 0.70 (0.57-0.76) from the 1-year version and 0.66 (0.56-0.77) from the 3-month version. A median kappa of 0.39 (0.19-0.70) and 0.58 (0.39-0.73) was observed for concurrent validation of the 1-year and 3-month versions respectively. Except for gastro-oesophageal reflux symptoms, no differences were observed on the prevalence of clinically relevant symptoms. Conclusion The revised Talley-BDQ is reliable, with excellent reproducibility and validity. There were few differences in reported symptom rates between the 3-month and 1-year recall time versions of the questionnaire. A 1-year recall time may more efficiently capture infrequent or subtle symptoms.

Original languageEnglish (US)
Pages (from-to)1237-1247
Number of pages11
JournalAlimentary Pharmacology and Therapeutics
Volume31
Issue number11
DOIs
StatePublished - Jun 2010

Fingerprint

Gastrointestinal Diseases
Gastroesophageal Reflux
Reproducibility of Results
Surveys and Questionnaires

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Measurement of abdominal symptoms by validated questionnaire : A 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframe. / Rey, E.; Locke, G. R.; Jung, H. K.; Malhotra, A.; Choung, R. S.; Beebe, T. J.; Schleck, C. D.; Zinsmeister, A. R.; Talley, N. J.

In: Alimentary Pharmacology and Therapeutics, Vol. 31, No. 11, 06.2010, p. 1237-1247.

Research output: Contribution to journalArticle

Rey, E. ; Locke, G. R. ; Jung, H. K. ; Malhotra, A. ; Choung, R. S. ; Beebe, T. J. ; Schleck, C. D. ; Zinsmeister, A. R. ; Talley, N. J. / Measurement of abdominal symptoms by validated questionnaire : A 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframe. In: Alimentary Pharmacology and Therapeutics. 2010 ; Vol. 31, No. 11. pp. 1237-1247.
@article{6cf143fc50874ab1976c8a27ac14cc75,
title = "Measurement of abdominal symptoms by validated questionnaire: A 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframe",
abstract = "Background Rome III incorporates changes in the definition of functional gastrointestinal disorder that involve a 3-month recall time for symptoms, rather than 1-year. Aim To validate a new version of the Talley-Bowel Disease Questionnaire (Talley-BDQ) and assess the impact of recall time period on the prevalence of symptoms. Methods A sample of community residents were randomly mailed a survey using 1-year (n = 396) or 3-month recall period (n = 374). We evaluated the reliability and the concurrent validity of the two versions of the questionnaire. The proportions of subjects reporting symptoms in the two versions were compared. Results The median (IQR) kappa on symptom-related questions was 0.70 (0.57-0.76) from the 1-year version and 0.66 (0.56-0.77) from the 3-month version. A median kappa of 0.39 (0.19-0.70) and 0.58 (0.39-0.73) was observed for concurrent validation of the 1-year and 3-month versions respectively. Except for gastro-oesophageal reflux symptoms, no differences were observed on the prevalence of clinically relevant symptoms. Conclusion The revised Talley-BDQ is reliable, with excellent reproducibility and validity. There were few differences in reported symptom rates between the 3-month and 1-year recall time versions of the questionnaire. A 1-year recall time may more efficiently capture infrequent or subtle symptoms.",
author = "E. Rey and Locke, {G. R.} and Jung, {H. K.} and A. Malhotra and Choung, {R. S.} and Beebe, {T. J.} and Schleck, {C. D.} and Zinsmeister, {A. R.} and Talley, {N. J.}",
year = "2010",
month = "6",
doi = "10.1111/j.1365-2036.2010.04288.x",
language = "English (US)",
volume = "31",
pages = "1237--1247",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Measurement of abdominal symptoms by validated questionnaire

T2 - A 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframe

AU - Rey, E.

AU - Locke, G. R.

AU - Jung, H. K.

AU - Malhotra, A.

AU - Choung, R. S.

AU - Beebe, T. J.

AU - Schleck, C. D.

AU - Zinsmeister, A. R.

AU - Talley, N. J.

PY - 2010/6

Y1 - 2010/6

N2 - Background Rome III incorporates changes in the definition of functional gastrointestinal disorder that involve a 3-month recall time for symptoms, rather than 1-year. Aim To validate a new version of the Talley-Bowel Disease Questionnaire (Talley-BDQ) and assess the impact of recall time period on the prevalence of symptoms. Methods A sample of community residents were randomly mailed a survey using 1-year (n = 396) or 3-month recall period (n = 374). We evaluated the reliability and the concurrent validity of the two versions of the questionnaire. The proportions of subjects reporting symptoms in the two versions were compared. Results The median (IQR) kappa on symptom-related questions was 0.70 (0.57-0.76) from the 1-year version and 0.66 (0.56-0.77) from the 3-month version. A median kappa of 0.39 (0.19-0.70) and 0.58 (0.39-0.73) was observed for concurrent validation of the 1-year and 3-month versions respectively. Except for gastro-oesophageal reflux symptoms, no differences were observed on the prevalence of clinically relevant symptoms. Conclusion The revised Talley-BDQ is reliable, with excellent reproducibility and validity. There were few differences in reported symptom rates between the 3-month and 1-year recall time versions of the questionnaire. A 1-year recall time may more efficiently capture infrequent or subtle symptoms.

AB - Background Rome III incorporates changes in the definition of functional gastrointestinal disorder that involve a 3-month recall time for symptoms, rather than 1-year. Aim To validate a new version of the Talley-Bowel Disease Questionnaire (Talley-BDQ) and assess the impact of recall time period on the prevalence of symptoms. Methods A sample of community residents were randomly mailed a survey using 1-year (n = 396) or 3-month recall period (n = 374). We evaluated the reliability and the concurrent validity of the two versions of the questionnaire. The proportions of subjects reporting symptoms in the two versions were compared. Results The median (IQR) kappa on symptom-related questions was 0.70 (0.57-0.76) from the 1-year version and 0.66 (0.56-0.77) from the 3-month version. A median kappa of 0.39 (0.19-0.70) and 0.58 (0.39-0.73) was observed for concurrent validation of the 1-year and 3-month versions respectively. Except for gastro-oesophageal reflux symptoms, no differences were observed on the prevalence of clinically relevant symptoms. Conclusion The revised Talley-BDQ is reliable, with excellent reproducibility and validity. There were few differences in reported symptom rates between the 3-month and 1-year recall time versions of the questionnaire. A 1-year recall time may more efficiently capture infrequent or subtle symptoms.

UR - http://www.scopus.com/inward/record.url?scp=77951855182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951855182&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2010.04288.x

DO - 10.1111/j.1365-2036.2010.04288.x

M3 - Article

C2 - 20222912

AN - SCOPUS:77951855182

VL - 31

SP - 1237

EP - 1247

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 11

ER -